Autoimmune diseases arise from a failure of immune tolerance — the immune system attacks self-tissue due to Th1/Th17 imbalance, regulatory T-cell deficiency, and dysregulated cytokine networks. Peptide research approaches autoimmunity through immune modulation: restoring regulatory T-cell function, dampening inflammatory cytokines, and repairing barrier tissues that drive antigen exposure.
1. Thymosin Alpha-1 — Central Immune Modulator
Thymosin Alpha-1 (TA1) is the best-studied immune-modulatory peptide. It promotes regulatory T-cell (Treg) expansion, restores Th1/Th2/Th17 balance, and reduces the excessive autoimmune inflammatory response without globally suppressing immune function. TA1 has been used clinically in multiple countries for immune regulation.
Dosing Protocol: 1.5 mg SubQ twice weekly for 4 weeks (induction), then 1.5 mg once weekly for maintenance. Cycles of 8–12 weeks with 4-week breaks are common.
2. BPC-157 — Barrier Repair / Systemic Anti-Inflammatory
Many autoimmune conditions are driven or worsened by gut permeability (“leaky gut”) that floods the bloodstream with antigens triggering immune overreaction. BPC-157 repairs intestinal barrier integrity, reduces systemic inflammatory cytokines (TNF-α, IL-6), and modulates the vagus nerve pathways that regulate systemic inflammation.
Dosing Protocol: 500 mcg oral BPC-157 (arginate form) daily to target gut barrier repair. Can stack with 250 mcg SubQ for dual systemic action. Cycle: 8–12 weeks.
3. KPV — Local Tissue Anti-Inflammatory
KPV (Lys-Pro-Val) is a potent anti-inflammatory tripeptide that inhibits NF-κB activation in multiple tissue types. It reduces IL-6, IL-8, and TNF-α release from immune cells and has shown particular efficacy in inflammatory bowel conditions — commonly associated with systemic autoimmune flares.
Dosing Protocol: 200–500 mcg SubQ daily, or oral for GI-focused autoimmune conditions. Topical formulations exist for skin-targeted autoimmunity (psoriasis, eczema). Cycle: 6–8 weeks.
4. VIP — Regulatory T-Cell Support / Neuropeptide Modulation
Vasoactive Intestinal Peptide (VIP) is a potent immunomodulatory neuropeptide that promotes Treg differentiation, inhibits Th17 cells (key drivers of autoimmunity), and reduces the production of autoimmune-driving cytokines IL-17 and IL-23. VIP has demonstrated efficacy in rheumatoid arthritis, Crohn’s, and multiple sclerosis models.
Dosing Protocol: 25–50 mcg SubQ or intranasal daily. Best used in moderate-severity autoimmune flares. Cycle: 4–8 weeks with monitoring.
Thymosin Alpha-1 restores the upstream regulatory T-cell imbalance driving the autoimmune response. BPC-157 addresses gut permeability — the most common trigger for antigen flooding that perpetuates autoimmunity. KPV and VIP suppress the local and systemic inflammatory cascades while VIP specifically inhibits the Th17 pathway most implicated in autoimmune tissue damage.
- Goldstein AL et al. (2018). Thymosin alpha-1 in immune regulation. Int Immunopharmacol. DOI: 10.1016/j.intimp.2018.11.002
- Seiwerth S et al. (2018). BPC-157 and gut-immune axis. Peptides. DOI: 10.1016/j.peptides.2018.10.008
- Getting SJ et al. (2004). KPV and NF-κB inhibition. J Biol Chem. DOI: 10.1074/jbc.M400521200
- Gonzalez-Rey E et al. (2006). VIP and regulatory T-cell induction. PNAS. DOI: 10.1073/pnas.0409229102
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).